Rheumnow Podcast

ACR22 Year in Review Report Can computers tell the difference between RA & PsA? NSAIDs and CV risk in Inflammatory Arthritis Prelude to a Meeting (ACR22) (11.11.2022) QD205 - RA Activity During Pregnancy (abstract #0955) Sputum anti-CCP the new diagnostic test in at-risk RA? Switching Between JAK Inhibiters in RA Treatment Choices and Mortality in RA ILd

Treatment Considerations in Axial Spondyloarthritis What Happens after you stop biologics? What lifestyle factors affect TNF inhibitor efficacy in AxSpA? Which is better for AxSpA? IL-17i or TNFi? Women vs. Men: Response to Treatment in Seronegative Arthritis

Opioids and Health Care Utilization in PsA and AS Reproductive health in a post-Roe world Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression Sunday (Day 2): ACR 22 Daily Recap Tapering TNFi in nonradiographic AxSpA The CONSUL Trial: Ankylosing Spondylitis

Comorbidities in Ankylosing Spondylitis Early Diagnosis of Axial Spondyloarthritis Fertility issues in SpA Gender in AxSpa Inadequate Dosing of Hydroxychloroquine Leads to Hospitalizations in SLE JAK inhibitors in rheumatic diseases Opioid use in PsA and SpA

ACR22 Daily Recap: Saturday Recap AI Future of Sacroiliitis Assessment Artificial Intelligence in Detecting Sacroiliitis Axial Spondyloarthritis: gender differences Can we alter neonatal gut microbiome to prevent spondyloarthritis? Comorbidities in Axial Spondyloarthritis Do Disease Activity Measures Really Capture AS in Women?

Dr. Jack Cush and Dr. Arthur Kavanaugh discuss, dissect and deliberate the sessions and data presented at the ACR22 meeting in Philadelphia.

Wednesday - SpA Panelists: Drs. Lianne Gensler, Antoni Chan, Akhil Sood, Eric Dein, Sheila Reyes, Catherine Sims

Get the Skinny on Bimekizumab in PsA Dr. Janet Pope discusses abstract presented at ACR22 Convergence in Philadelphia, PA. L02: Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study Low dose steroids can negatively impact bone healthDr. Janet Pope discusses abstract L01 presented at ACR22 Convergence in Philadelphia, PA.  L01: Impact of Glucocorticoid Dosing and Anti-Osteoporotic Treatment on Bone Health in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Longitudinal Cohort Study The First Head to Head trial in Axial Spondyloarthritis Dr. Lianne Gensler discusses abstract L15 presented at ACR22 Convergence in Philadelphia, PA. L15: Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study Why Clinical Trials? Dr. Guillermo Valenzuela talks about the importance of clinical trials from ACR22 Convergence in Philadelphia, PA.

RheumNow faculty to recap the best and most interesting data presented at ACR2022 in the area of PsA. Tuesday - PsA (7pm ET) Panelists: Drs. Rachel Tate, Robert Chao, Olga Petryna, Elaine Husni, Patricia Harkins